RPS18

Across TCGA pan-cancer cohorts, RPS18 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPS18 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RPS18 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPS18 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

GBM, LUAD, and CCRCC are the cancer types where RPS18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.650	0.774	.004	14	view →
LUAD	OS	Quartile	II,III,IV	0.440	0.748	.009	13	view →
CCRCC	OS	Median	All	0.756	0.921	.006	7	view →
LSCC	DFS	Median	II,III,IV	0.819	0.582	.021	6	view →
HNSC	DFS	Median	III,IV	0.911	0.684	.011	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPS18–GBM (DFS)

Open the GBM breakdown →